The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.

Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M
J Urol. 2005 174 (2): 547-52; discussion 552

PMID: 16006889 · DOI:10.1097/01.ju.0000165569.48372.4c

MeSH Terms (13)

Androgen Antagonists Anilides Cost-Benefit Analysis Decision Support Techniques Drug Therapy, Combination Gonadotropin-Releasing Hormone Humans Male Nitriles Prostatic Neoplasms Quality of Life Sensitivity and Specificity Tosyl Compounds

Connections (1)

This publication is referenced by other Labnodes entities: